A Multicentric, Open Label, Balanced, Randomized, Two-Treatment, Two-Period With Two Consecutive Profile in Single Period, Two-Sequence, Crossover, Multiple Oral Dose, Comparative Bioavailability Study of Etoposide Capsules 100 mg (Intas Pharmaceuticals Limited, India) With Vepesid 100 mg (Etoposide) Soft Capsules (Cheplapharm Arzneimittel GmbH) in Adult Patients With Platinum Resistant or Refractory Ovarian Cancer.

Intas Pharmaceuticals Ltd India0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年1月9日

试验速览

阶段: 未知
状态: 尚未招募
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•Participants are eligible to be included in the study only if all of the following criteria apply:
•1. Participant must sign an ICF indicating that she understands the purpose of, and procedures required for the study as described in this protocol and is willing to participate in the study.
•2. Participant must be woman, aged greater than 18 years of age, at the time of signing the informed consent.
•3. Documented medical history of histo-pathologically or cytologically confirmed diagnosis of epithelial carcinoma of the ovary, fallopian tube cancer or primary peritoneal carcinoma.
•4. Documented past medical history of platinum resistant or refractory disease as per standard clinical and Gynecologic Cancer Intergroup Committee (GCIC) criteria: Platinum-resistant disease, defined as disease progression less than or equal to 6 months after completing a platinum-based regimen (3- 6 cycles). Platinum-refractory disease: Lack of response (CR or PR) or disease progression while receiving the platinum-based therapy.
•5. Participant who are already receiving and tolerating oral etoposide monotherapy at dose of 100 mg once daily as per the independent clinical judgment of the Investigator for at least one previous cycle (i.e. 21 days treatment in a 28-days cycle).
•6. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 at screening and baseline.
•7. Body mass index (BMI) within the range 18.5 â?? 30 kg per m2 (inclusive) at screening and baseline.
•8. Life expectancy of greater than or equal to 12 weeks at screening and baseline.
•9. Participants if have received radiotherapy (regardless of site & dose), a gap of 28 days must be maintained between the last dose of radiotherapy and baseline.
•10. Participant with adequate hematologic, liver and renal function at screening and/or baseline as defined in schedule of assessments. Bone marrow function: ANC greater or equal to 1500 per mm3 without granulocyte colony-stimulating factor support at screening and at baseline, Platelet count greater or equal to 100,000 per mm3 without transfusion at screening and at baseline, Hemoglobin greater or equal to 9 g per dL without erythropoietin dependency and without packed red blood cell transfusion at screening and at baseline. Renal function: Creatinine Clearance greater than 50 mL per min as calculated by Cockcroft Gault formula at screening and at baseline. Hepatic function: Bilirubin less than or equal to ULN at screen, ALT, AST, Alkaline phosphatase less or equal to 2.5 times ULN at screening (ALT, AST, Alkaline phosphatase less than or equal to5 times ULN will be allowed in cases where increase is related to liver metastases), Serum Albumin greater than or equal to 3 g per dL at screening.
•11. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of less than 1% per year), with low user dependency when used consistently and correctly, during the intervention period and for at least 6 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during the study and for a period of at least 6 months. The investigator should evaluate the effectiveness of the contraceptive

排除标准

•Any potential participant who meets any of the following criteria will be excluded from participating in the study:
•1. History of clinically significant medical condition including but not limited to cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances; any severe, acute, or chronic medical, psychiatric or social condition; or laboratory abnormality that as per Investigators opinion may either (a) not be in the best interest of the participant (e.g., compromise the well-being), (b) interfere with the informed consent process and or with compliance with the requirements of the trial, or (c) prevent, limit, or confound the protocol-specified assessments or (d) result in the variation of absorption or metabolism of drug, i.e., ulcerative colitis, or gastrointestinal disease.
•2. Known allergies, hypersensitivity, or intolerance to etoposide capsules 100 mg or its excipients (refer to SmPC of Vepesid).
•3. Contraindications to the use of etoposide as per SmPC of Vepesid at screening and at baseline.
•4. Had major surgery, (e.g., requiring general anesthesia) within 4 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study or within 30 days after the last dose of study intervention administration. NOTE: Participants with planned minor surgical procedures to be conducted under local anesthesia may participate.
•5. History of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HBsAg or anti-HCV at screening.
•6. History of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at screening.
•7. History of drug abuse within 1 year before screening or positive test result(s) for drugs of abuse (including barbiturates, opiates, cocaine, cannabinoids, amphetamines and benzodiazepines) at baseline with exception of drugs prescribed for medical reason.
•8. History of alcohol abuse within 1 year before screening or positive test result(s) for alcohol abuse at baseline.
•9. Lymphoma, leukemia, or any malignancy within the past 5 years from screening except for malignancy under study, basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years; carcinoma in situ of the cervix; or malignancy, which is considered cured with minimal risk of recurrence.
•10. Participant s unable to ingest oral medications.
•11. Known CNS disease at screening, except for treated asymptomatic CNS metastases, provided all of the following criteria are met: Only supratentorial metastases allowed (i.e., no metastases to midbrain, pons, medulla, or spinal cord), No evidence of interim progression or hemorrhage after completion of CNS-directed therapy, No ongoing requirement for corticosteroids as therapy for CNS disease, No stereotactic radiation within 14 days or whole-brain radiation within 28 days prior to randomization.
•12. Leptomeningeal disease at screening and baseline.
•13. Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for greater than or equal to 4 weeks prior to ba

研究者

发起方

Intas Pharmaceuticals Ltd India

相似试验

尚未招募

不适用

A Study of Clozapine Extended Release Capsule 200 mg Once Daily in Adult Schizophrenic Patients.

CTRI/2019/11/022073Intas Pharmaceuticals Limited

进行中（未招募）

1 期

Comparative pharmacokinetics study (study to know the amount of study drug (cyclophosphamide) in your blood at specified time points – to understand what body does to this study drug) of two products of cyclophosphamide powder for oral solution and Cyclophosphamide Tablets 50 mg in adult patients with breast cancerAdult female patients with breast cancer.MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2021-004897-77-Outside-EU/EEAIntas Pharmaceuticals Ltd.

已完成

不适用

A study of cyclophosphamide powder for oral solution in adult patients with breast cancer.

CTRI/2021/11/037948Intas Pharmaceuticals LtdIndia

尚未招募

不适用

A study of Risperidone Long Acting Injection 25 Mg/ Vial In Patients Needing Treatment For Schizophrenia And/or Maintenance Therapy For Bipolar I Disorder

CTRI/2022/05/042538Intas Pharmaceuticals Ltd India

已完成

不适用

Bioequivalence study of asenapine sublingual tablets in patients

CTRI/2013/11/004152Amneal Pharmaceuticals LLC USA48